RetiSpec Announces Partnership With Gentex To Commercialize Alzheimer's Disease Detection Technology

A Toronto-based medical imaging startup using UMN technology has formed a new collaboration to help that technology reach the market.

RetiSpec is an artificial intelligence (AI) medical imaging company developing tools for the early detection of disease biomarkers in the eye. Gentex develops, engineers and manufactures electro-optical products for a wide variety of industries, including automotive, aerospace, fire protection and medical.

"The Gentex-RetiSpec partnership reinforces our commitment to bring to market RetiSpec's novel retinal imaging technology, a widely scalable and affordable way to accurately detect Alzheimer's Disease at both the symptomatic and pre-symptomatic stages," said Eliav Shaked, CEO of RetiSpec. "We are excited about the prospect of partnering with Gentex and leveraging its vast expertise and innovative technologies in machine vision, imaging and electronics manufacturing."

Read the full news release in Yahoo Finance.